Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 4/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | WNT3A | P56704 | 2/20 | 0.47 |
| ▸ | RORC | P51449 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5028493 | 0.92 | SMN1; SMN2 (0.50) | HPGDKDM4EHSD17B10SMN1; SMN2RAB9A | |
| SCHEMBL8232855 | 0.90 | WNT3A (0.47) | HPGDKDM4EALDH1A1LMNAHSD17B10 | |
| SCHEMBL5031524 | 0.90 | WNT3A (0.47) | HPGDKDM4ELMNAHSD17B10MAPT | |
| SCHEMBL5031527 | 0.90 | GAA (0.51) | HPGDKDM4EALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL5031517 | 0.90 | WNT3A (0.54) | HPGDKDM4EALDH1A1LMNAHSD17B10 | |
| SCHEMBL5033031 | 0.88 | KMT2A (0.56) | HPGDKDM4EALDH1A1LMNAHSD17B10 | |
| SCHEMBL5032991 | 0.87 | PSEN1 (0.52) | WNT3ARORC | |
| SCHEMBL5034882 | 0.87 | POLB (0.52) | KDM4EALDH1A1LMNAMAPTKMT2A | |
| SCHEMBL5031521 | 0.85 | LMNA (0.47) | LMNASMN1; SMN2 | |
| SCHEMBL5030729 | 0.85 | ALDH1A1 (0.56) | HPGDKDM4EALDH1A1LMNAHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1998612-A2 | SUBSTITUTED BIARYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | Synta Pharmaceuticals Corporation (US) | 2008-12-10 | — | — | EP | claimed |
| US-20070254363-A1 | Substituted biaryl compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2007-11-01 | — | — | US | claimed |
| WO-2007087442-A2 | SUBSTITUTED BIARYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2007-08-02 | — | — | WO | claimed |
| US-20140121217-A1 | SUBSTITUTED BIARYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2014-05-01 | — | — | US | disclosed |
| US-20140121217-A1 | SUBSTITUTED BIARYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2014-05-01 | — | — | US | disclosed |
| US-8623871-B2 | Substituted biaryl compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2014-01-07 | — | — | US | disclosed |
| US-8623871-B2 | Substituted biaryl compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2014-01-07 | — | — | US | disclosed |
| US-8623871-B2 | Substituted biaryl compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2014-01-07 | — | — | US | disclosed |
| EP-1998612-A2 | SUBSTITUTED BIARYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | Synta Pharmaceuticals Corporation (US) | 2008-12-10 | — | — | EP | disclosed |
| US-20070254363-A1 | Substituted biaryl compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2007-11-01 | — | — | US | disclosed |
| US-20070254363-A1 | Substituted biaryl compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2007-11-01 | — | — | US | disclosed |
| US-20070254363-A1 | Substituted biaryl compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2007-11-01 | — | — | US | disclosed |
| WO-2007087442-A2 | SUBSTITUTED BIARYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2007-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254363-A1 | Substituted biaryl compounds for inflammation and immune-related uses | CCR1, CCR3, CXCR2 | HPGD 2712/4885KDM4E 2323/4885ALDH1A1 865/4885 |
| US-20140121217-A1 | SUBSTITUTED BIARYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | CCR1, CCR3, CXCR2 | HPGD 2712/4885KDM4E 2323/4885ALDH1A1 865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.